Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety Abstract #1756

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.
Aim(s): Aim of this study is to evaluate efficacy and safety of PPI and SSA in MEN1 related ZES.
Materials and methods: Eighteen pts with MEN1 related ZES were retrospectively evaluated (12 m, 6 f, mean age 36 yrs) for a median follow-up of 104 months (range 6-203). Gastrinoma was located in pancreas(7), pancreas and duodenum(7), duodenum(4). All pts were treated with PPI only for at least 6 months (median 12, range 6-19), afterwards SSA were added.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
#2132 Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands. Duodeno-pancreatic neuroendocrine tumors (DP-NET) represent the most frequent type of NET in MEN1. Their prognosis and treatment strategy is debated.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Roberta Modica
#1093 38 Years of Experience in a Single Centre on Neuroendocrine Pancreatico-Duodenal Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome
Introduction: Multiple Endocrine Neoplasia type 1 (MEN1) syndrome has an autosomal dominant transmission. Combination of tumors: parathyroid, pituitary and pancreatico-duodenal (PD) NETs. PD NETs in MEN1 syndrome show propensity for malignant degeneration.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Valbona Lico
#1774 Report on the Clinicopathological Characteristics of 548 Romanian Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs
Introduction: In Romania, treatment with somatostatin analogs (SSA) for neuroendocrine tumors (NETs) is based on the National Clinical Practice Guideline for the Diagnostic and Treatment of NETs and is reimbursed by the National Health Insurance Company since 2008.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD, Prof. Fica Simona
#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data
Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: DR. Valeria Ramundo